Multi-centre trial evaluating efti in combination with pembrolizumab and chemotherapy in patients with non-small cell lung ...

An announcement from Immutep Ltd ( (AU:IMM) ) is now available.

IMP761, an experimental immunotherapy Immutep is developing for multiple sclerosis (MS) and other autoimmune conditions, has shown a promising safety profile in an ongoing Phase 1 clinical trial ...

Dec. 18, 2024 — Until now, scientists have been unable to determine how metformin, a Type 2 diabetes medication that lowers blood sugar, works. A study provided direct evidence in mice that it ...

Verition Fund Management LLC’s holdings in Immutep were worth $57,000 at the end of the most recent quarter. Other hedge funds have also added to or reduced their stakes in the company.

Dr. Frédéric Triebel, CSO of Immutep, said: "We are very encouraged by the safety data generated to date for IMP761, the world's first LAG-3 agonist antibody, in this Phase I setting.

Clinical-stage company Immutep (ASX:IMM) has announced new findings published in Science Immunology that resolve how human lymphocyte activation gene 3 (LAG-3) binds to its main ligand MHC Class II ...

Immutep reports no adverse events in Phase I trial of IMP761, a LAG-3 agonist for autoimmune diseases, with more data expected in 2025. Immutep Limited has released promising initial safety data ...

Favourable safety profile for world’s first LAG-3 agonist, IMP761, with no treatment related adverse events to dateAdditional ...

Dr. Frédéric Triebel, CSO of Immutep, said:“We are very encouraged by the safety data generated to date for IMP761, the world's first LAG-3 agonist antibody, in this Phase I setting.